Zentalis(US:ZNTL)2025-11-10 21:11Financial Performance - Zentalis Pharmaceuticals reported cash, cash equivalents, and marketable securities of $280.7 million as of September 30, 2025, providing a runway into late 2027[8] - Research and development expenses for Q3 2025 were $23.0 million, a decrease of 37.5% from $36.8 million in Q3 2024[8] - General and administrative expenses for Q3 2025 were $10.8 million, down 26% from $14.6 million in Q3 2024[8] - Total operating expenses for Q3 2025 were $33.7 million, compared to $51.4 million in Q3 2024, reflecting a reduction of 34.6%[8] - The net loss for Q3 2025 was $26.7 million, compared to a net loss of $40.2 million in Q3 2024, representing a 33.5% improvement[8] - The company reported a net loss per share of $0.37 for Q3 2025, compared to $0.56 for Q3 2024[12] Clinical Trials - The DENALI Phase 2 trial for azenosertib is on track, with topline data expected by year-end 2026, potentially supporting accelerated approval[4] - Enrollment is ongoing in DENALI Part 2a, targeting approximately 30 patients at two dose levels: 400mg QD 5:2 and 300mg QD 5:2[4] - The TETON Phase 2 trial in uterine serous carcinoma has completed enrollment, with results expected to be published in the first half of 2026[4] Strategic Positioning - Zentalis maintains a robust financial foundation to support the development of azenosertib, with ongoing engagement with trial investigators and medical conferences[3]